PDCD1 and colorectal carcinoma: Immunotherapy, thanks to the discovery of anti-PD-1 and PD-L1 antibodies, is a promising new treatment option for CRC patients; however, it has been effective in only a selective number of CRC patients with high-frequency microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) [30].